Recent Updates
Recently added Catalysts
AVLN Positive Sentiment

Avalyn Announces Multiple Presentations at the European Respiratory Society International Congress 2026

Monday, August 24, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Avalyn Pharma Inc. announced its participation in the European Respiratory Society International Congress 2026. The presentations will focus on integrating patient perspectives into clinical trial design and data modeling related to AP01 distribution in the lungs. This reflects Avalyn's commitment to innovative inhaled therapies.

Market Sentiment Analysis

POSITIVE FACTORS

  • Avalyn is actively participating in a major international congress.
  • The presentations highlight innovative approaches in clinical trial design.
  • Integration of patient perspectives is a progressive step in research.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~47 mo
Minimal dilution risk
Lead asset
AP01
Phase 2 · Pulmonary Fibrosis

Full Press Release Details

Presentations describe integration of patient perspective into clinical trial design and data modeling AP01 distribution in the lungs BOSTON, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc. (Nasdaq: AVLN), a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the

Frequently Asked Questions

What is the focus of Avalyn's presentations at the congress?

Avalyn's presentations will focus on integrating patient perspectives into clinical trial design.

When is the European Respiratory Society Congress 2026?

The congress is scheduled for August 2026.

What is AP01 in relation to Avalyn's research?

AP01 refers to a therapy being studied for its distribution in the lungs.

What type of company is Avalyn Pharma?

Avalyn Pharma is a clinical-stage biopharmaceutical company specializing in inhaled therapies.

ShareAdd on Google
Tags: AVLN Viatris Investor Conferences Healthcare Avalyn Pharma ERS Congress 2026 clinical trials inhaled therapies patient perspective
Last updated: Aug 24, 2026

Biotech snapshot

Cash runway
$414M liquidity · $9M/mo burn
~47 mo
Minimal dilution risk
Lead asset
AP01Phase 2
Pulmonary Fibrosis →